UT MDACC/Regional Cancer Centers
Welcome,         Profile    Billing    Logout  
 22 Trials 
20 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Meric-Bernstam, Funda
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
4200
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/27
12/28
NCT04946864: A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Suspended
1/2
65
US, RoW
APG-2575, APG2575, Palbociclib
Ascentage Pharma Group Inc.
Breast Cancer, Solid Tumor, Adult
08/24
10/24
CBX-12-101, NCT04902872: Study of CBX-12 in Subjects with Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting
1/2
130
US
CBX-12
Cybrexa Therapeutics
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
03/25
06/25
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, ZIIHERA®, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
09/25
09/25
StarBridge-1, NCT05320588: A Study in Patients With Advanced Cancers

Recruiting
1/2
332
US
BIO-106, Pembrolizumab, Keytruda
BiOneCure Therapeutics Inc.
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
04/24
04/27
NCT04092673: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting
1/2
30
US
eFT226, Selective translation inhibitor, Sotorasib, Lumarkus, Fulvestrant, Faslodex, Abemaciclib, Verzenia, Trastuzumab, Herceptin
Effector Therapeutics
Solid Tumor, Adult
12/24
03/25
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting
1/2
300
Canada, US
LCB84, Anti-PD-1 monoclonal antibody
LigaChem Biosciences, Inc., AntibodyChem Biosciences, Inc.
Advanced Solid Tumors
01/27
05/27
FONTANA, NCT05797168: Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Recruiting
1/2
396
Europe, Canada, Japan, US, RoW
AZD5335, Saruparib (AZD5305), AZD5305, Bevacizumab, Avastin, Carboplatin, Paraplatin
AstraZeneca
Ovarian Cancer, Lung Adenocarcinoma
01/28
01/28
NCT04586270: A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

Terminated
1
47
Europe, US
TAS0612
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors
11/24
11/24
SGNCEA5C-001, NCT06131840: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Recruiting
1
494
Europe, Canada, US
PF-08046050, SAR445953; SGN-CEACAM5C, bevacizumab
Seagen, a wholly owned subsidiary of Pfizer, Sanofi
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
08/29
02/30
CUSP06-1001, NCT06234423: A Study of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Recruiting
1
180
US
CUSP06
OnCusp Therapeutics, Inc.
Ovarian Cancer, Solid Tumor
05/27
08/27
NCT03843359: A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Active, not recruiting
1
97
Europe, Canada, Japan, US, RoW
GSK3745417, Dostarlimab
GlaxoSmithKline
Neoplasms
04/24
03/25
IMGN151-1001, NCT05527184: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Recruiting
1
423
US
IMGN151
AbbVie
Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
02/27
02/27
NCT06457997: A Study of PHN-010 in Patients with Advanced Solid Tumors

Recruiting
1
273
US
PHN-010
Pheon Therapeutics
Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Advanced Solid Tumor, Advanced Cancer
04/27
07/27
TH1902-CTR-0001, NCT04706962: TH1902 in Patients With Advanced Solid Tumors

Active, not recruiting
1
70
Canada, US
TH1902, TH1902 peptide-drug conjugate
Theratechnologies, PPD DEVELOPMENT, LP, Altasciences Company Inc., Windtree Therapeutics, Syneos Health, Innovaderm Research Inc.
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
12/25
01/26
MER-XMT-1660-1, NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27
NCT04058756: Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Active, not recruiting
1
120
Europe, Canada, US, RoW
PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors
04/30
04/30
NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing
N/A
US
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Meric-Bernstam, Funda
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
4200
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/27
12/28
NCT04946864: A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Suspended
1/2
65
US, RoW
APG-2575, APG2575, Palbociclib
Ascentage Pharma Group Inc.
Breast Cancer, Solid Tumor, Adult
08/24
10/24
CBX-12-101, NCT04902872: Study of CBX-12 in Subjects with Advanced or Metastatic Refractory Solid Tumors

Active, not recruiting
1/2
130
US
CBX-12
Cybrexa Therapeutics
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
03/25
06/25
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, ZIIHERA®, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
09/25
09/25
StarBridge-1, NCT05320588: A Study in Patients With Advanced Cancers

Recruiting
1/2
332
US
BIO-106, Pembrolizumab, Keytruda
BiOneCure Therapeutics Inc.
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
04/24
04/27
NCT04092673: Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

Recruiting
1/2
30
US
eFT226, Selective translation inhibitor, Sotorasib, Lumarkus, Fulvestrant, Faslodex, Abemaciclib, Verzenia, Trastuzumab, Herceptin
Effector Therapeutics
Solid Tumor, Adult
12/24
03/25
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Recruiting
1/2
390
US
ACR-368, prexasertib, Gemcitabine, OncoSignature
Acrivon Therapeutics, GOG Foundation
Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma
07/26
12/27
NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting
1/2
300
Canada, US
LCB84, Anti-PD-1 monoclonal antibody
LigaChem Biosciences, Inc., AntibodyChem Biosciences, Inc.
Advanced Solid Tumors
01/27
05/27
FONTANA, NCT05797168: Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Recruiting
1/2
396
Europe, Canada, Japan, US, RoW
AZD5335, Saruparib (AZD5305), AZD5305, Bevacizumab, Avastin, Carboplatin, Paraplatin
AstraZeneca
Ovarian Cancer, Lung Adenocarcinoma
01/28
01/28
NCT04586270: A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer

Terminated
1
47
Europe, US
TAS0612
Taiho Oncology, Inc.
Advanced or Metastatic Solid Tumors
11/24
11/24
SGNCEA5C-001, NCT06131840: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Recruiting
1
494
Europe, Canada, US
PF-08046050, SAR445953; SGN-CEACAM5C, bevacizumab
Seagen, a wholly owned subsidiary of Pfizer, Sanofi
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
08/29
02/30
CUSP06-1001, NCT06234423: A Study of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Recruiting
1
180
US
CUSP06
OnCusp Therapeutics, Inc.
Ovarian Cancer, Solid Tumor
05/27
08/27
NCT03843359: A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

Active, not recruiting
1
97
Europe, Canada, Japan, US, RoW
GSK3745417, Dostarlimab
GlaxoSmithKline
Neoplasms
04/24
03/25
IMGN151-1001, NCT05527184: First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

Recruiting
1
423
US
IMGN151
AbbVie
Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
02/27
02/27
NCT06457997: A Study of PHN-010 in Patients with Advanced Solid Tumors

Recruiting
1
273
US
PHN-010
Pheon Therapeutics
Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Advanced Solid Tumor, Advanced Cancer
04/27
07/27
TH1902-CTR-0001, NCT04706962: TH1902 in Patients With Advanced Solid Tumors

Active, not recruiting
1
70
Canada, US
TH1902, TH1902 peptide-drug conjugate
Theratechnologies, PPD DEVELOPMENT, LP, Altasciences Company Inc., Windtree Therapeutics, Syneos Health, Innovaderm Research Inc.
Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
12/25
01/26
MER-XMT-1660-1, NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors

Hourglass Jul 2024 - Dec 2024 : Initial dose escalation and backfill cohort data for solid tumors
Recruiting
1
319
US
XMT-1660
Mersana Therapeutics
Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma
12/26
05/27
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27
NCT04058756: Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Active, not recruiting
1
120
Europe, Canada, US, RoW
PDR001
Novartis Pharmaceuticals
Advanced Solid Tumors
04/30
04/30
NCT04507503: Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing
N/A
US
TAS-120, Futibatinib
Taiho Oncology, Inc.
Advanced Cholangiocarcinoma
 
 

Download Options